Skip to main content
logo
Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea flag South Korea · Delayed Price · Currency is KRW
17,990
-40 (-0.22%)
Sep 1, 2026, 3:30 PM KST

Onconic Therapeutics Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
82,17253,39214,83821,0569560
Revenue Growth
179.26%259.82%-29.53%22064.25%58.33%-
Gross Profit
82,14953,38114,83521,054-14,838-8,342
Operating Income
17,30312,619-4,7982,231-14,838-8,342
Net Income
24,25115,784-8,0931,682-14,432-15,149
Earnings Per Share
-347.92-247.4572.78-624.23-661.40
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
62,61652,73543,00030,10027,31618,861
Total Debt
270.83125.8308.47353.6650.72189.04
Net Cash (Debt)
62,34552,60942,69129,74727,26518,672
Net Cash Growth
38.64%23.23%43.52%9.10%46.02%-
Net Cash Per Share
-1159.651305.391286.701179.32815.23

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
16,80611,395-7,8414,140-14,961-8,859
Capital Expenditures
-316.64-302.9-141.28-1,157-2,575-2.67
Free Cash Flow
16,49011,092-7,9822,983-17,536-8,861
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
99.97%99.98%99.98%99.99%--
Operating Margin
21.06%23.64%-32.33%10.60%-15618.48%-13903.24%
Pretax Margin
27.03%25.70%-67.00%3.14%-15191.48%-25247.72%
Profit Margin
29.51%29.56%-54.54%7.99%-15191.48%-25247.72%
FCF Margin
20.07%20.77%-53.79%14.16%-18458.96%-14769.11%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
33.6855.11----
P/FCF Ratio
49.5478.41----
PS Ratio
9.9416.2911.90---